Last reviewed · How we verify
Afrezza plus One Drop | Premium
Afrezza plus One Drop | Premium is a Rapid-acting insulin Small molecule drug developed by Informed Data Systems, Inc.. It is currently FDA-approved for Type 1 diabetes mellitus, Type 2 diabetes mellitus. Also known as: insulin inhalation.
Afrezza is a rapid-acting inhaled insulin that delivers insulin directly to the lungs for quick absorption into the bloodstream to lower blood glucose.
Afrezza is being studied in combination with One Drop | Premium for the treatment of Type 2 Diabetes Mellitus. A randomized controlled trial, NCT03313960, is evaluating the effectiveness of Afrezza plus One Drop | Premium compared to One Drop | Premium alone.
At a glance
| Generic name | Afrezza plus One Drop | Premium |
|---|---|
| Also known as | insulin inhalation |
| Sponsor | Informed Data Systems, Inc. |
| Drug class | Rapid-acting insulin |
| Target | Insulin receptor |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Afrezza uses a proprietary pulmonary delivery system to administer human insulin as a dry powder that is inhaled and absorbed through the respiratory tract. This allows for faster insulin onset compared to subcutaneous injection, with peak levels reached in approximately 12-15 minutes. The One Drop integration provides digital glucose monitoring and insulin dosing guidance to optimize glycemic control.
Approved indications
- Type 1 diabetes mellitus
- Type 2 diabetes mellitus
Common side effects
- Cough
- Hypoglycemia
- Throat irritation
- Headache
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Afrezza plus One Drop | Premium CI brief — competitive landscape report
- Afrezza plus One Drop | Premium updates RSS · CI watch RSS
- Informed Data Systems, Inc. portfolio CI
Frequently asked questions about Afrezza plus One Drop | Premium
What is Afrezza plus One Drop | Premium?
How does Afrezza plus One Drop | Premium work?
What is Afrezza plus One Drop | Premium used for?
Who makes Afrezza plus One Drop | Premium?
Is Afrezza plus One Drop | Premium also known as anything else?
What drug class is Afrezza plus One Drop | Premium in?
What development phase is Afrezza plus One Drop | Premium in?
What are the side effects of Afrezza plus One Drop | Premium?
What does Afrezza plus One Drop | Premium target?
Related
- Drug class: All Rapid-acting insulin drugs
- Target: All drugs targeting Insulin receptor
- Manufacturer: Informed Data Systems, Inc. — full pipeline
- Therapeutic area: All drugs in Diabetes
- Indication: Drugs for Type 1 diabetes mellitus
- Indication: Drugs for Type 2 diabetes mellitus
- Also known as: insulin inhalation
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing